Bioretec Q2'25: Heikommat myyntiluvut ja haasteet

Bioretec's weak Q2 earnings were a disappointment compared to expectations. The company's revenue and gross margin % decreased sharply, and the simultaneous increase in operational costs doubled the operating loss. Bioretec's interim CEO Sarah Hubar-Fisher provides more details in an interview with analyst Antti Siltanen.Topics00:00 Introduction00:13 Q2 summary02:18 Negative revenue impact of ended Spartan Medical distribution deal03:06 Weak performance in Europe and the United States05:46 Status of country-specific processes in terms of RemeOs sales 06:55 Expectations for the rest of the year08:48 Reasons to focus more on sales agent model09:43 Main bottlenecks and obstacles for increasing sales11:11 Indication expansion in US12:09 RemeOs's sales outlook in the United States13:11 Sales agent model14:50 Opex level15:48 Increased working capital level16:50 R&D pipeline18:11 Development of single-use tools19:50 Reimbursements21:00 Learnings in RemeOs’s commercialization22:16 Final words